GlassScriptPhysician profile
Tasmina Sheikh
NPI 1659376150
$6,739.65
in general payments reported to CMS, 2019-2025
32 companies · $450 in 2025
The $450 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,229 · 2020: $664 · 2021: $1,126 · 2022: $1,090 · 2023: $1,283 · 2024: $897 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,549 · Education: $81.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,548.59 |
| Education | $81.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $991.25 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $949.58 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $835.90 | 2021-2024 | Vraylar |
| Lundbeck LLC | $508.14 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $500.89 | 2019-2022 | |
| Allergan, INC. | $361.87 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $267.71 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $266.94 | 2021-2025 | Caplyta |
| Bausch Health US, LLC | $262.50 | 2019-2025 | Aplenzin, Wellbutrin |
| Otsuka America Pharmaceutical, INC. | $235.01 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $212.60 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $157.30 | 2019-2023 | Spravato |
| Livanova USA, INC. | $151.29 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Merck Sharp & Dohme LLC | $104.83 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $102.32 | 2020-2025 | Fanapt |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $91.15 | 2023-2024 | Quviviq |
| Alkermes, INC. | $83.68 | 2021-2022 | |
| Shire North American Group INC | $80.16 | 2019 | |
| Eisai INC. | $75.21 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $64.96 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $64.95 | 2024-2025 | Cobenfy |
| Arbor Pharmaceuticals, INC. | $55.65 | 2019-2020 | |
| Almatica Pharma LLC | $55.09 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Ironshore Pharmaceuticals INC. | $54.41 | 2019-2020 | |
| Corium, LLC | $40.39 | 2022-2023 | Azstarys |
| Adlon Therapeutics L.P. | $34.00 | 2019 | |
| Avanir Pharmaceuticals, INC. | $33.89 | 2019 | |
| Axsome Therapeutics, INC. | $32.01 | 2023 | Auvelity |
| Boston Scientific Corporation | $22.97 | 2022 | |
| Alfasigma USA, INC. | $14.57 | 2020 | |
| Noven Therapeutics, LLC | $14.50 | 2024 | Secuado, Xelstrym |
| Tms Neurohealth Centers INC. | $13.93 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tasmina Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.